Suppliers and packagers for TURALIO

TURALIO

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810	NDA	Daiichi Sankyo Inc.	65597-407-20	1 BOTTLE in 1 CARTON (65597-407-20) / 120 CAPSULE in 1 BOTTLE	2023-02-01
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810	NDA	Daiichi Sankyo Inc.	65597-407-28	1 BOTTLE in 1 CARTON (65597-407-28) / 28 CAPSULE in 1 BOTTLE	2023-02-01

Suppliers for the Pharmaceutical Drug: TURALIO

Last updated: July 29, 2025

Introduction

TURALIO (pazopanib) is an oral targeted therapy developed by Novartis for the treatment of unresectable or metastatic dermatofibrosarcoma protuberans (DFSP), a rare type of skin cancer. Since its approval, understanding the supply chain dynamics for TURALIO becomes vital for stakeholders including healthcare providers, investors, and healthcare policymakers. This report provides an in-depth analysis of the primary manufacturers, raw material suppliers, distribution channels, and the competitive landscape that underpin the supply of TURALIO.

Manufacturers and Formulation Sources

Novartis as the Principal Developer and Marketer

Novartis AG formulates and markets TURALIO. Its integrated manufacturing facilities in various regions—including Europe and North America—produce the active pharmaceutical ingredient (API) and finished pharmaceutical products (FPP). Novartis's vertically integrated supply chain allows control over quality, production capacity, and compliance with regulatory standards such as Good Manufacturing Practices (GMP).

API Production

The core of TURALIO is pazopanib, a multi-targeted tyrosine kinase inhibitor. The API synthesis depends on complex chemical processes requiring specialized suppliers of key intermediates and catalysts. While Novartis may produce the API in-house for certain markets, it often relies on a network of strategic API suppliers to hedge against supply risks and meet global demand.

Major API manufacturers for pazopanib are located predominantly in Asia-Pacific and Europe. These suppliers are often identified via industry intelligence reports, but Novartis’s specific API sourcing remains proprietary—shared only with regulatory authorities and select partners.

Formulation and Packaging

Once the API is secured, Novartis's manufacturing network handles formulation, encapsulation, and packaging. These operations are deployed across multiple facilities to ensure supply resilience. The formulation process includes blending, capsule filling, and final packaging, all adhering to strict quality controls.

Raw Material Suppliers and Components

Active Pharmaceutical Ingredient (API)

The procurement of pazopanib API is central to TURALIO’s supply. API synthesis involves raw chemicals, solvents, catalysts, and intermediates sourced from specialized chemical suppliers. Key raw materials include chloropyrimidines, amino alcohols, and various heterocyclic compounds. These raw materials are generally sourced from large chemical suppliers in China, India, and Europe.

Excipients and Packaging Materials

TURALIO capsules contain excipients like microcrystalline cellulose, magnesium stearate, or other filler materials. These are supplied globally by companies such as Dow Chemical, FMC, and other established excipient manufacturers, which have rigorous quality standards suited to pharmaceutical use.

Packaging components include blister packs and bottle caps, supplied by packaging companies with global distribution networks, including Amcor, Gerresheimer, or WestRock.

Distribution Network and Supply Chain Dynamics

Global Distribution

Novartis operates a sophisticated distribution infrastructure, partnering with major pharmaceutical logistics providers such as DHL, FedEx, and local distributors, to ensure timely delivery to hospitals, pharmacies, and healthcare systems across Europe, North America, and Asia.

Difficulties in Supply Chain

Supply chain challenges for TURALIO include API shortages, geopolitical issues, regulatory delays, and capacity constraints. The complex global sourcing of raw materials, especially during disruptions like the COVID-19 pandemic, has prompted Novartis to diversify suppliers and increase inventory buffers.

Regulatory and Compliance Considerations

Suppliers of both the API and excipients must adhere to stringent GMP standards. Regular audits by Novartis and regulatory authorities (e.g., FDA, EMA) ensure supplier compliance, maintaining product quality and safety.

Competitive Landscape of Suppliers

API Suppliers

Leading API suppliers for pazopanib include chemical manufacturing giants such as Sun Pharmaceutical Industries (India), Dr. Reddy's Laboratories (India), and smaller specialized API producers in China and Europe. These firms possess the expertise to produce high-purity API batches at scale.

Third-party Contract Manufacturers

Novartis may engage Contract Development and Manufacturing Organizations (CDMOs) for formulation, filling, and packaging services. Notable CDMOs in this space include Catalent, Siegfried, and Recipharm. These entities enable flexible capacity, rapid scaling, and supply chain security.

Suppliers of Raw Materials and Excipients

Material suppliers such as BASF, Dow Chemical, and FMC contribute ingredients that comply with pharmaceutical standards, ensuring compatible and safe excipients for TURALIO capsules.

Supply Chain Risks and Mitigation Strategies

• Raw Material Scarcity: Suppliers of key intermediates face geopolitical and market volatility. Novartis mitigates this through multiple sourcing agreements and strategic stockpiling.
• Manufacturing Capacity Constraints: To prevent shortages, Novartis invests in expanding capacity and establishing secondary manufacturing sites.
• Regulatory Delays: Maintaining strong relationships with supply chain partners and proactive regulatory engagement reduce the risk of approval delays.
• Quality Compliance: Rigorous audits and quality agreements ensure supplier adherence to compliance standards, minimizing recall risks.

Key Trends Influencing Supply

• Global API Market Growth: Increased demand for targeted therapies drives API manufacturing capacity expansion, benefiting TURALIO’s supply stability.
• Supply Chain Digitalization: Use of blockchain and IoT enhances tracking, transparency, and accountability across the supply chain.
• Sustainability Initiatives: Suppliers adopting greener manufacturing practices contribute to sustainable supply chain resilience.

Conclusion

The supply of TURALIO hinges on a complex, globally integrated network involving Novartis’s internal manufacturing capabilities, diverse API suppliers—primarily in Asia and Europe—and a broad base of excipient manufacturers. The critical success factors include robust supplier qualification processes, diversified sourcing strategies, and vigilant management of geopolitical and regulatory risks. Ensuring a reliable supply requires continuous investments in manufacturing capacity, supply chain transparency, and strategic partnerships.

---

Key Takeaways

• Novartis maintains tight control over TURALIO’s manufacturing, but relies on a multi-supplier network for API and excipients.
• API suppliers for pazopanib are predominantly based in India, China, and Europe, providing competitive manufacturing capacity.
• Supply chain resilience depends on diversified sourcing, proactive regulatory compliance, and robust logistics partnerships.
• The market’s growth and geopolitical shifts necessitate ongoing supplier diversification and capacity expansion.
• Advances in supply chain digitalization and sustainability are increasingly integral to securing a stable TURALIO supply.

---

FAQs

1. Who are the primary API suppliers for TURALIO?
   Pazopanib’s API is sourced from multiple suppliers, chiefly in India (e.g., Sun Pharmaceutical, Dr. Reddy’s) and China, with European suppliers playing a secondary role to diversify risk.

2. Does Novartis manufacture TURALIO in-house or via partnerships?
   Novartis manages key parts of TURALIO manufacturing internally, including formulation and packaging, but collaborates with third-party CDMOs for capacity expansion.

3. What are common challenges in the supply of TURALIO?
   Challenges include raw material shortages, geopolitical disruptions, regulatory delays, and capacity constraints—mitigated through supply diversification and strategic inventory management.

4. Are there alternative suppliers for excipients used in TURALIO?
   Yes, excipients such as microcrystalline cellulose and magnesium stearate are supplied globally by companies like Dow Chemical and FMC, with multiple sources to ensure continuity.

5. How does supply chain digitalization impact TURALIO’s availability?
   Digital tools improve traceability, quality assurance, and inventory management, reducing risks and improving responsiveness to market demands.

---

References

[1] Novartis. TURALIO (pazopanib) prescribing information.
[2] Industry reports on global API manufacturing capacity and trends.
[3] Supply chain risk management publications in pharmaceutical manufacturing.
[4] Regulatory agency guidelines (FDA, EMA) for pharmaceutical sourcing and quality standards.
[5] Market analysis reports on targeted cancer therapies and supply chain dynamics.